NFSG
ORMP icon

Newbridge Financial Services Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Newbridge Financial Services Group’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$2.64K – 1369
2025
Q3 		$2.64K Hold
1,000
– – ﹤0.01% 1107
2025
Q2 		$2.25K Buy
+1,000
New +$2.21K ﹤0.01% 1130
2024
Q2 		– Sell
-657
Closed -$1.92K – 1192
2024
Q1 		$1.92K Hold
657
– – ﹤0.01% 997
2023
Q4 		$1.52K Hold
657
– – ﹤0.01% 994
2023
Q3 		$1.72K Hold
657
– – ﹤0.01% 1096
2023
Q2 		$2.35K Hold
657
– – ﹤0.01% 1115
2023
Q1 		$1.43K Hold
657
– – ﹤0.01% 1241
2022
Q4 		$7.9K Hold
657
– – ﹤0.01% 960
2022
Q3 		$4K Hold
657
– – ﹤0.01% 1090
2022
Q2 		$3K Hold
657
– – ﹤0.01% 1120
2022
Q1 		$6K Hold
657
– – ﹤0.01% 1069
2021
Q4 		$9K Buy
+657
New +$13.7K ﹤0.01% 938

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
AF
Aquamarine Financial George Town $1.37B AUM
SCM
SB Capital Management Encino, California $273M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Newbridge Financial Services Group's ORMP Position: Q4 2025 in Review

Newbridge Financial Services Group sold out of Oramed Pharmaceuticals (ORMP) in Q4 2025, closing a stake of 1,000 shares — an estimated $2.64K sold.

Newbridge Financial Services Group first reported a position in ORMP in Q4 2021 and held it in 12 quarters. The position peaked at $9K in Q4 2021. 57 funds tracked by Wall St. Rank hold ORMP as of Q4 2025.

  • Newbridge Financial Services Group reported no remaining Oramed Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Newbridge Financial Services Group sold 1,000 Oramed Pharmaceuticals shares in Q4 2025, an estimated $2.64K.
  • Newbridge Financial Services Group first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 12 quarters.
  • Newbridge Financial Services Group's Oramed Pharmaceuticals position peaked at $9K in Q4 2021.
  • 57 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2025.

Based on Newbridge Financial Services Group's 13F filing for Q4 2025, filed 21 Jan 2026.